With increasing knowledge about medicinal effects of marijuana along with the growth of legal medical use, several investments have been made in marijuana stocks for developing novel medications for the treatment of various human diseases. From these medical pursuits, CR701 is currently undergoing trial.
Cannabinoids have shown excellent outcomes for relieving pain compared to opioids. As with other cannabinoids, CR701 acts on specific endocannabinoid receptors in the body. CR701 has been evaluated in rats for the treatment of neuropathic pain, that comes from nerve damage.
When these animals were simulated to a model of increased pain (whether to painful stimuli or repeated non-painful stimuli), CR701 led to a marked reduction of response to both types of sensitization.
Specific cannabinoid receptors in the body include CB1 and CB2. The former receptors are mainly located in the brain, spinal cord, and some peripheral organs, while the latter receptors are predominant in immune cells involved in the process of pain sensation and inflammation.
Cara Therapeutics, the developing company of CR701, is concerned with creating medications that have an analgesic effect without adversely affecting the brain and spinal cord. Despite its promising therapeutic abilities in animals, clinical trials have fallen off the radar in the past year. Even if these trials are conducted, it would be at least 4 years before seeing CR701 in human clinical setting, following necessary approval by the food and drug administration.
In general, no deaths were documented as a result of using marijuana in 2016, compared to more than 20,000 deaths due to opioid overdose in 2015. However, the information regarding the potential side effects CR701 is still lacking.
If you are considering to use medical cannabis, you should consult a medical professional or your local physician first.